HALIFAX, Nov. 29 /CNW/ - ImmunoVaccine Technologies Inc. (IVT) announced
today that it has successfully scaled-up the manufacturing process for its
vaccine platform, Vaccimax(R). This work validates the suitability of the
platform for commercial applications in therapeutic cancer and infectious
disease indications. The manufacturing development was performed at Dalton
Pharma Services, a Health Canada and GMP compliant pharmaceutical
manufacturing and development company. Today's results show that IVT's vaccine
delivery platform can be produced on a commercial scale.
IVT's product, VacciMax(R), is a vaccine-enhancement platform comprised
of a special emulsion of liposomes, antigens, adjuvants and oil. To prepare
VacciMax(R) for human cancer clinical trials, IVT has been developing its
platform to meet all regulatory requirements including manufacturing in a GMP
setting. The ability to scale-up, under GMP or good manufacturing practices,
is mandatory for various worldwide regulatory authorities, such as the FDA. By
successfully producing VacciMax(R) at a commercially relevant batch size, IVT
plans to license its vaccine technology worldwide for the therapy and
prevention of cancer and infectious diseases.
"We are pleased to collaborate with IVT and wish to congratulate the
entire team on meeting such an important milestone. The successful scale-up of
VacciMax(R) was a direct result of the Dalton and IVT teams' strong technical
capabilities and project management skills," remarked Peter Pekos, President
and CEO of Dalton Pharma Services.
IVT's testing verified that development batches produced at Dalton at an
increasing scale retained their expected biological activity. Analytical
testing also showed that the various elements of the platform are chemically
stable. The latest batch produced at the 50 litre scale also met manufacturing
and chemical specifications.
"VacciMax(R) is a novel technology with broad potential," said Marc
Mansour, Vice President of Research and Development. "Proving that our
technology can be manufactured in a GMP environment and is scalable, will
enable us to aid the development of vaccines for numerous therapeutic cancer
and preventative infectious disease applications"
ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company
focused on the commercialization of its patented VacciMax(R) platform.
VacciMax(R) is a novel technology that can aid the development of new vaccines
in human health applications with potential for both therapeutic cancer
applications and preventative infectious disease vaccines. The opportunities
for market applications and medical benefits are broad, and are currently
being applied to cervical cancer, with potential for melanoma, breast,
prostate and colon cancer treatments, as well as prevention therapies for
influenza and other infectious diseases. www.immunovaccine.com
For further information:
For further information: Jennifer Ayotte, Communications, (902) 423-6610
x 315, email@example.com; Brian Lowe, Vice President IVT, (902)